Literature DB >> 4329097

Further studies on streptozotocin therapy for a multiple-hormone-producing islet cell carcinoma.

I M Murray-Lyon, J Cassar, R Coulson, R Williams, P C Ganguli, J C Edwards, K W Taylor.   

Abstract

A patient with a multiple-hormone-producing islet cell carcinoma, who had previously been successfully treated with streptozotocin, was given three further infusions of this drug because of the redevelopment of gastric hypersecretion. Although some evidence of damage to the gastrinsecreting cells was obtained, the fasting plasma gastrin was not significantly altered and the patient died from a perforated duodenal ulcer. Serum insulin levels were considerably reduced and the patient became mildly diabetic but the main complication of treatment was a severe though reversible renal tubular defect. At necropsy considerable quantities of gastrin, but low levels of insulin and glucagon were extracted from a tumour metastasis.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4329097      PMCID: PMC1411787          DOI: 10.1136/gut.12.9.717

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  Immunoassay of insulin with insulin-antibody precipitate.

Authors:  C N HALES; P J RANDLE
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

2.  Use of glucose oxidase, peroxidase, and O-dianisidine in determination of blood and urinary glucose.

Authors:  A S HUGGETT; D A NIXON
Journal:  Lancet       Date:  1957-08-24       Impact factor: 79.321

3.  Extractable glucagon of the human pancreas.

Authors:  A J KENNY
Journal:  J Clin Endocrinol Metab       Date:  1955-09       Impact factor: 5.958

4.  Radioimmunoassay of glucagon released from isolated guinea-pig islets of Langrrhans incubated in vitro.

Authors:  J C Edwards; S L Howell; K W Taylor
Journal:  Biochim Biophys Acta       Date:  1970-08-14

5.  Significance of human plasma insulin Sephadex fractions.

Authors:  S J Goldsmith; R S Yalow; S A Berson
Journal:  Diabetes       Date:  1969-12       Impact factor: 9.461

6.  Effect of streptozotocin on qualitative aspects of plasma insulin in a patient with a malignant islet cell tumor.

Authors:  W G Blackard; A R Garcia; C L Brown
Journal:  J Clin Endocrinol Metab       Date:  1970-08       Impact factor: 5.958

7.  Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin.

Authors:  I M Murray-Lyon; A L Eddleston; R Williams; M Brown; B M Hogbin; A Bennett; J C Edwards; K W Taylor
Journal:  Lancet       Date:  1968-10-26       Impact factor: 79.321

8.  Treatment of insulinoma with streptozotocin.

Authors:  Y Arnould; H A Ooms; P A Bastenie
Journal:  Lancet       Date:  1969-06-14       Impact factor: 79.321

9.  Studies of the diabetogenic action of streptozotocin.

Authors:  A Junod; A E Lambert; L Orci; R Pictet; A E Gonet; A E Renold
Journal:  Proc Soc Exp Biol Med       Date:  1967-10

10.  Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin.

Authors:  R N Arison; E I Ciaccio; M S Glitzer; J A Cassaro; M P Pruss
Journal:  Diabetes       Date:  1967-01       Impact factor: 9.461

View more
  5 in total

1.  Effect of streptozotocin on erythrocyte and retinal superoxide dismutase.

Authors:  R Crouch; G Kimsey; D G Priest; A Sarda; M G Buse
Journal:  Diabetologia       Date:  1978-07       Impact factor: 10.122

Review 2.  Tumour-associated hormonal products.

Authors:  J Landon; J G Ratcliffe; L H Rees; A P Scott
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1974

3.  Streptozotocin treatment for malignant insulinoma.

Authors:  J O'Donnell; I V Allen; J C Hunter; E M McIlrath; D A Montgomery
Journal:  Ir J Med Sci       Date:  1974-05       Impact factor: 1.568

4.  Radio-immunoassay of gastrin in human plasma.

Authors:  P C Ganguli; W M Hunter
Journal:  J Physiol       Date:  1972-01       Impact factor: 5.182

5.  Endocrine sequelae of cancer and cancer treatments.

Authors:  Charles J Stava; Camilo Jimenez; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2007-11-20       Impact factor: 4.442

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.